3,412
Views
11
CrossRef citations to date
0
Altmetric
Research Article

Microfluidic-based fabrication and characterization of drug-loaded PLGA magnetic microspheres with tunable shell thickness

ORCID Icon, , , , , , , , & show all
Pages 692-699 | Received 08 Jan 2021, Accepted 15 Mar 2021, Published online: 05 Apr 2021

References

  • Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J. (2007). Magnetic nanoparticles for drug delivery. Nano Today 2:22–32.
  • Bokharaei M, Saatchi K, Häfeli UO. (2017). A single microfluidic chip with dual surface properties for protein drug delivery. Int J Pharm 521:84–91.
  • Bray F, Ferlay J, Soerjomataram I, et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424.
  • Breslauer DN, Muller SJ, Lee LP. (2010). Generation of monodisperse silk microspheres prepared with microfluidics. Biomacromolecules 11:643–7.
  • Cao W-Z, Zhou Z-Q, Jiang S, et al. (2019). Efficacy and safety of drug-eluting beads for transarterial chemoembolization in patients with advanced hepatocellular carcinoma. Exp Ther Med 18:4625–30.
  • Choi SY, Kwak BK, Shim HJ, et al. (2015). MRI traceability of superparamagnetic iron oxide nanoparticle-embedded chitosan microspheres as an embolic material in rabbit uterus. Diagn Interv Radiol 21:47–53.
  • Cilliers R, Song Y, Kohlmeir EK, et al. (2008). Modification of embolic-PVA particles with MR contrast agents. Magn Reson Med 59:898–902.
  • Coletta M, Nicolini D, Benedetti Cacciaguerra A, et al. (2017). Bridging patients with hepatocellular cancer waiting for liver transplant: all the patients are the same? Transl Gastroenterol Hepatol 2:78–84.
  • Gong Q, Gao X, Liu W, et al. (2019). Drug-loaded microbubbles combined with ultrasound for thrombolysis and malignant tumor therapy. Biomed Res Int 2019:1–11.
  • Hung L-H, Teh S-Y, Jester J, Lee AP. (2010). PLGA micro/nanosphere synthesis by droplet microfluidic solvent evaporation and extraction approaches. Lab Chip 10:1820–5.
  • Jain RA. (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21:2475–90.
  • Lewis AL, Taylor RR, Hall B, et al. (2006). Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 17:1335–43.
  • Li Y, Yan D, Fu F, et al. (2017). Composite core–shell microparticles from microfluidics for synergistic drug delivery. Sci China Mater 60:543–53.
  • Liang B, Zhao D, Liu Y, et al. (2020). Chemoembolization of liver cancer with doxorubicin-loaded CalliSpheres microspheres: plasma pharmacokinetics, intratumoral drug concentration, and tumor necrosis in a rabbit model. Drug Deliv Transl Res 10:185–91.
  • Malagari K, Pomoni M, Moschouris H, et al. (2014). Chemoembolization of hepatocellular carcinoma with HepaSphere 30–60 μm. Safety and efficacy study. Cardiovasc Intervent Radiol 37:165–75.
  • Melchiorre F, Patella F, Pescatori L, et al. (2018). DEB-TACE: a standard review. Future Oncol 14:2969–84.
  • Nakamura H, Hashimoto T, Oi H, Sawada S. (1989). Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 170:783–6.
  • Nanaki S, Siafaka PI, Zachariadou D, et al. (2017). PLGA/SBA-15 mesoporous silica composite microparticles loaded with paclitaxel for local chemotherapy. Eur J Pharm Sci 99:32–44.
  • Obayemi JD, Danyuo Y, Dozie-Nwachukwu S, et al. (2016). PLGA-based microparticles loaded with bacterial-synthesized prodigiosin for anticancer drug release: effects of particle size on drug release kinetics and cell viability. Mater Sci Eng C Mater Biol Appl 66:51–65.
  • Parkin DM, Bray F, Ferlay J, Pisani P. (2005). Global Cancer Statistics, 2002. CA Cancer J Clin 55:74–108.
  • Patel AA, Solomon JA, Soulen MC. (2005). Pharmaceuticals for intra-arterial therapy. Semin Intervent Radiol 22:130–8.
  • Peng S, Hong T, Liang W, et al. (2019). A multichannel microchip containing 16 chambers packed with antibody-functionalized beads for immunofluorescence assay. Anal Bioanal Chem 411:1579–89.
  • Piscaglia F, Bolondi L. (2010). The intermediate hepatocellular carcinoma stage: should treatment be expanded? Dig Liver Dis 42:S258–S63.
  • Prasad N, Perumal J, Choi C-H, et al. (2009). Generation of monodisperse inorganic–organic janus microspheres in a microfluidic device. Adv Funct Mater 19:1656–62.
  • Song DS, Choi JY, Yoo SH, et al. (2013). DC bead transarterial chemoembolization is effective in hepatocellular carcinoma refractory to conventional transarteral chemoembolization: a pilot study. Gut Liver 7:89–95.
  • Song JE, Kim DY. (2017). Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol 9:808–14.
  • Tan Y, Sheng J, Tan H, Mao J. (2019). Pancreas lipiodol embolism induced acute necrotizing pancreatitis following transcatheter arterial chemoembolization for hepatocellular carcinoma: a case report and literature review. Medicine 98:e18095–e100.
  • Torre LA, Bray F, Siegel RL, et al. (2015). Global cancer statistics, 2012. CA Cancer J Clin 65:87–108.
  • Villanueva A. (2019). Hepatocellular carcinoma. N Engl J Med 380:1450–62.
  • Wang L, Liu W, Li S, et al. (2016). Fast fabrication of microfluidic devices using a low-cost prototyping method. Microsyst Technol 22:677–86.
  • Wu B, Zhou J, Ling G, et al. (2018). CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. World J Surg Oncol 16:69–76.
  • Xu H, Yang R, Wang X, et al. (2014). Symptomatic pulmonary lipiodol embolism after transarterial chemoembolization for hepatic malignant tumor: clinical presentation and chest imaging findings. Chin Med J 127:675–9.
  • Yu J-S, Kim JH, Chung J-J, Kim KW. (2009). Added value of diffusion-weighted imaging in the MRI assessment of perilesional tumor recurrence after chemoembolization of hepatocellular carcinomas. J Magn Reson Imaging 30:153–60.
  • Zhao C, Ma SPZCY. (2019). Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma. J BUON 24:1150–66.